Starton Therapeutics Files Patent Application for the Use of Multi-Specific Antibody-Based Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood…
- The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with multi-specific (i.e. bi- and tri-specific) antibodies.
- Recent Phase 1b trial data indicates that STAR-LLD does not appear to significantly increase immune checkpoints associated with T cell exhaustion, thought to be a key factor in multiple myeloma (MM) relapse.
PARAMUS, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary continuous delivery technologies, announced today that it has filed a patent application for the use of multi-specific (i.e., bi- and tri-specific) antibody-based therapies in combination with the Company’s proprietary, continuous low-dose IMiD, which is a subcutaneous administration of lenalidomide, STAR-LLD, for the treatment of cancer.
“We are pleased to announce the filing of this provisional patent application,” stated Pedro Lichtinger, Chairman and Chief Executive Officer of Starton. “Although lenalidomide and other IMiDs are being studied in combination with multi-specific antibodies, side effect profiles are thought to limit widespread acceptance by oncologists. We believe our continuous subcutaneous delivery of a low-dose formulation of lenalidomide has the potential to improve the side effect profile while sustaining T-cell persistence and response durability.”
About STAR-LLD
STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD with 20% of animals in this cohort tumor-free after 100 days; by contrast, there was a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1b clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (1 CR and 5 PRs); no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy. The Phase 1b clinical study concluded that continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade > 2 drug-related hematologic toxicity.
About Starton Therapeutics
Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer live better, for longer. Starton’s proprietary technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit www.startontx.com.
Forward Looking Statements
All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and, except as required by law, Starton undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Investor Relations Contact
Eric Ribner
Managing Director
LifeSci Advisors
eric@lifesciadvisors.com
Media Contact
Jason Braco, PhD
LifeSci Communications
jbraco@lifescicomms.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
